Depomed Inc. Dec. 26, 2012, announced that its lawsuits against two filers of abbreviated new drug applications for Gralise (gabapentin) have been dismissed.
Gralise is a once-daily treatment approved by the Food and Drug Administration for managing postherpetic neuralgia (PHN).
Watson Laboratories Inc. has withdrawn its Gralise ANDA and Par Pharmaceutical Inc. has amended its Gralise ANDA and is no longer seeking approval of the ANDA prior to the expiration of Depomed’s patents listed for Gralise in the FDA Orange Book, Depomed said.
As a result, the U.S. District Court for the District of New Jersey has granted the ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.